Additionally, we noted that C75 treatment skewed primary effector CD4 T cells toward a Th2-like phenotype, which could be detrimental to some immune responses, including anti-tumor T cell reactions that require IFN-γ. The gene discussed is IFNG; the disease is neoplasm.